Company intelligence / Profile preview

NatureCell

Seoul, Seoul, South Korea

Ownership: Private
Employees: ~77
Development stage: Other

Overview

NatureCell is the first Korean company to receive FDA Breakthrough Therapy Designation for its autologous adipose-derived mesenchymal stem cell therapy, Jointstem, in the treatment of osteoarthritis; clinical trials have produced positive safety and efficacy data over a three-year follow-up period[2][3][6].

Therapeutic areas: Rheumatology
Modalities: Cell therapyStem cell therapy
Industry: Biotech

Drug pipeline

3 assets

JOINTSTEM

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on NatureCell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NatureCell.

Explore the full profile